142 related articles for article (PubMed ID: 14767342)
1. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer.
Le Visage C; Rioux-Leclercq N; Haller M; Breton P; Malavaud B; Leong K
J Urol; 2004 Mar; 171(3):1324-9. PubMed ID: 14767342
[TBL] [Abstract][Full Text] [Related]
2. HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer.
Rosato A; Banzato A; De Luca G; Renier D; Bettella F; Pagano C; Esposito G; Zanovello P; Bassi P
Urol Oncol; 2006; 24(3):207-15. PubMed ID: 16678050
[TBL] [Abstract][Full Text] [Related]
3. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice.
Harper E; Dang W; Lapidus RG; Garver RI
Clin Cancer Res; 1999 Dec; 5(12):4242-8. PubMed ID: 10632366
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy.
Lu Z; Yeh TK; Tsai M; Au JL; Wientjes MG
Clin Cancer Res; 2004 Nov; 10(22):7677-84. PubMed ID: 15570001
[TBL] [Abstract][Full Text] [Related]
5. Prevention of local tumor growth with paclitaxel-loaded microspheres.
Azouz SM; Walpole J; Amirifeli S; Taylor KN; Grinstaff MW; Colson YL
J Thorac Cardiovasc Surg; 2008 May; 135(5):1014-21. PubMed ID: 18455578
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy.
Mugabe C; Hadaschik BA; Kainthan RK; Brooks DE; So AI; Gleave ME; Burt HM
BJU Int; 2009 Apr; 103(7):978-86. PubMed ID: 19007363
[TBL] [Abstract][Full Text] [Related]
7. Bioadhesive characterization of poly(methylidene malonate 2.12) microparticle on model extracellular matrix.
Chan V; Liu KK; Le Visage C; Ju BF; Leong KW
Biomaterials; 2004 Aug; 25(18):4327-32. PubMed ID: 15046923
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) in an orthotopic bladder cancer model.
Tamura K; Kikuchi E; Konno T; Ishihara K; Matsumoto K; Miyajima A; Oya M
BMC Cancer; 2015 Apr; 15():317. PubMed ID: 25928041
[TBL] [Abstract][Full Text] [Related]
9. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo.
Konety BR; Lavelle JP; Pirtskalaishvili G; Dhir R; Meyers SA; Nguyen TS; Hershberger P; Shurin MR; Johnson CS; Trump DL; Zeidel ML; Getzenberg RH
J Urol; 2001 Jan; 165(1):253-8. PubMed ID: 11125420
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer.
Hadaschik BA; ter Borg MG; Jackson J; Sowery RD; So AI; Burt HM; Gleave ME
BJU Int; 2008 Jun; 101(11):1347-55. PubMed ID: 18384637
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral delivery of paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts.
Xie M; Zhou L; Hu T; Yao M
Anticancer Drugs; 2007 Apr; 18(4):459-66. PubMed ID: 17351398
[TBL] [Abstract][Full Text] [Related]
12. Comparison of anti-tumor efficacy of paclitaxel delivered in nano- and microparticles.
Chakravarthi SS; De S; Miller DW; Robinson DH
Int J Pharm; 2010 Jan; 383(1-2):37-44. PubMed ID: 19747969
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant.
Shikanov A; Shikanov S; Vaisman B; Golenser J; Domb AJ
Int J Pharm; 2008 Jun; 358(1-2):114-20. PubMed ID: 18406086
[TBL] [Abstract][Full Text] [Related]
14. Intravesical therapy with vinorelbine tartrate: antitumor activity in orthotopic murine cell carcinoma of the bladder.
Bonfil RD; Russo DM; Schmilovich AJ; Garcia-Palazzo IB
J Urol; 1997 Sep; 158(3 Pt 1):912-5. PubMed ID: 9258118
[TBL] [Abstract][Full Text] [Related]
15. Influence of pertussis toxin on superficial bladder carcinoma in rats.
Lümmen G; Sperling H; Eisenhardt A; vom Dorp F; Otto T; Rübben H
Urol Res; 2002 Jul; 30(3):199-203. PubMed ID: 12111185
[TBL] [Abstract][Full Text] [Related]
16. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
Zhang C; Qu G; Sun Y; Wu X; Yao Z; Guo Q; Ding Q; Yuan S; Shen Z; Ping Q; Zhou H
Biomaterials; 2008 Mar; 29(9):1233-41. PubMed ID: 18093646
[TBL] [Abstract][Full Text] [Related]
18. Protodynamic therapy for bladder cancer: in vitro results of a novel treatment concept.
Laihia JK; Pylkkänen L; Laato M; Boström PJ; Leino L
BJU Int; 2009 Nov; 104(9):1233-8. PubMed ID: 19466948
[TBL] [Abstract][Full Text] [Related]
19. Mathematical modeling and optimization of drug delivery from intratumorally injected microspheres.
Tzafriri AR; Lerner EI; Flashner-Barak M; Hinchcliffe M; Ratner E; Parnas H
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):826-34. PubMed ID: 15701873
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
Armstrong DK; Fleming GF; Markman M; Bailey HH
Gynecol Oncol; 2006 Nov; 103(2):391-6. PubMed ID: 16626792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
